Diabetes

Hello and welcome to the Pharmacy Times News Network. I’m Nicole Grassano your host for our Pharmacy Week in Review.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more.

Semaglutide offers a non-insulin solution that, in combination with healthy diet and exercise, may improve blood sugar.

How voice assistants are becoming more important in health care.

The 2017 Health Care Cost and Utilization Report examined medical and prescription drug spending, utilization, and average prices using health care claims data from 2013 through 2017 for Americans under the age of 65 who were covered by employer-sponsored insurance.

This medication, indicated for individuals with diabetes, will have a list price that is 50% lower than its current list price.

Top news of the day from across the health care landscape.

Novo Nordisk is seeking approval for fast-acting insulin aspart (Fiasp) as a new mealtime insulin for children and adolescents with type 1 diabetes.

Top news of the day from across the health care landscape.

The new mobile app gives those with type 2 diabetes accurate insulin doses with an 'on-the-go' convenience.

Researchers at Brigham and Women’s Hospital set out to evaluate the effects of switching insulins in those with type 2 diabetes.

Asking key questions can improve health outcomes and even save lives.

This study is the latest in a series that focuses on systematic accuracy in blood glucose test strip platforms.

Officials with the FDA have permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes.

Top news of the week from Specialty Pharmacy Times.

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.”

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.”

In a congressional hearing held on Capitol Hill today, the damaging impact of rising insulin prices was the centerpiece of a larger discussion on rising drug costs in the United States.

Analysis shows prices among all insulin types and products increased steadily between 2012 and 2016.

Health Care Professionals Should Be Aware of Classes of Medications and Conditions That May Affect Blood Glucose Levels.

Torrent Pharmaceuticals Limited has expanded its voluntary recall of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP.

Health care providers should individualize therapy to achieve the best possible outcomes.

The report authors noted that people with type 1 diabetes spent $5,705 on insulin in 2016, up from $2,864 in 2012.

Glucagon-like peptide-1 receptor agonists have been gaining popularity to treat diabetes. Does this one provide advantages over competitors?

The program launched by the Baltimore-based organizations is the first of its kind to leverage video technology and a public health practice known as Directly Observed Therapy, or DOT.